We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Leading Leukemia Lab Invests in Fluidigm Access Array™ and EP1™ Systems
Product News

Leading Leukemia Lab Invests in Fluidigm Access Array™ and EP1™ Systems

Leading Leukemia Lab Invests in Fluidigm Access Array™ and EP1™ Systems
Product News

Leading Leukemia Lab Invests in Fluidigm Access Array™ and EP1™ Systems


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Leading Leukemia Lab Invests in Fluidigm Access Array™ and EP1™ Systems"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Fluidigm Corporation has announced that MLL Munich Leukemia Laboratory has purchased Access Array™ and EP1™ Systems. The Access Array System is being used in combination with Roche's 454 GS FLX and GS Junior sequencing instruments, enabling high-throughput targeted deep-resequencing analyses. The EP1 System is being used for rare mutation detection studies and minimal residual disease investigations.

MLL combines diagnostic competences in cytomorphology, immunophenotyping, molecular genetics, and cytogenetics to provide patients with hematological malignancies with optimized, individualized, and reliable diagnoses.

"The number of molecular markers used to categorize myeloid neoplasms is constantly increasing. Amplicon-based next-generation sequencing is a suitable method to accurately detect and quantify the variety of molecular aberrations with high sensitivity (Kohlmann A et al., J Clin Oncol. 2010; 28:3858-65). We recently have added next-generation amplicon deep-sequencing to the portfolio of molecular diagnostic tests as part of our daily routine operations," said Prof. Torsten Haferlach, co-founder and CEO of MLL.

"Combining the Access Array and 454 sequencing systems delivers a robust and streamlined workflow that minimizes the number of manual steps required for targeted sequencing applications. MLL's installation is a perfect match for the capabilities of these systems that will enable high-quality analyses," said Gajus Worthington, president and CEO of Fluidigm. "Adding the EP1 System to the molecular diagnostic workflow will further enhance the detection and quantification of cancer mutations."
Advertisement